SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Sick Visit — Jacqueline du Pré

PatientJacqueline Mary du Pré
Date of birth1998-01-26
IdentifiersMRN HR-ML039-SYN; SSN (made up) 000-39-7062
Document date2026-06-15
AuthorImogen Thackeray-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Burning on passing urine and frequency for two days, with the tingling in her fingers back. [S]

History of Present Illness

Ms. du Pré called the clinic on the second day of burning on passing urine, frequency and urgency, and was seen the same day. Since yesterday she has felt feverish (37.8 °C at home) and the tingling in the fingers of her left hand, which had almost gone, has come back, with the fingers feeling a little clumsy on the fingerboard this morning. There is no new weakness, no unsteadiness, no change in vision and no back or loin pain. She has had no vaginal discharge and her last period was two weeks ago. She completed the first ocrelizumab course seven weeks ago. She is afraid this is a new relapse and asked whether she needs steroids again. She has had no thoughts of self-harm. [S]

ElementDetail
OnsetTwo days ago
SeverityBurning, frequency and urgency; low fever; no loin pain
ContextSeven weeks after the first ocrelizumab course; infections are more common on anti-CD20 therapy
Associated signs and symptomsOld tingling in the left fingers returned with the fever; no new deficit

Review of Systems

SystemResultFinding
ConstitutionalPositiveFeverish and tired since yesterday
GenitourinaryPositiveBurning, frequency and urgency; no blood in the urine, no discharge, no loin pain
NeurologicalPositiveReturning tingling in the left fingers since the fever; no new weakness, imbalance or visual change
GastrointestinalNegativeNo vomiting, diarrhea or abdominal pain
MusculoskeletalNegativeNo back pain
PsychiatricNegativeWorried about a relapse; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Nitrofurantoin macrocrystals 100 mg oral capsule, one capsule by mouth twice daily with food for 5 daysOne capsule twice daily for 5 daysOral route2026-06-15 to 2026-06-19completedS
Methylprednisolone 1000 mg injection, 1 g intravenously over one hour once daily for 3 days1 g daily for 3 daysIntravenous route2026-03-24 to 2026-03-26completedS
Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth dailyOne capsule dailyOral route2026-03-23activeS
Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion300 mg on days 1 and 15, then 600 mg every 6 monthsIntravenous route2026-04-13activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-15Body height173cmS
2026-06-15Body weight63.6kgS
2026-06-15Body mass index (BMI) [Ratio]21.3kg/m2S
2026-06-15Systolic blood pressure116mm[Hg]S
2026-06-15Diastolic blood pressure72mm[Hg]S
2026-06-15Heart rate92/minS
2026-06-15Respiratory rate16/minS
2026-06-15Body temperature37.8CelS
2026-06-15Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-06-15Leukocytes [#/volume] in Blood by Automated count10.210*3/uL4-11 10*3/uLNormalS
2026-06-15C reactive protein [Mass/volume] in Serum or Plasma14mg/L<=5 mg/LHighS

Physical Exam

Vital signs recorded on 2026-06-15; see the Vital Signs section. [S]

SystemFinding
GeneralWell, a little flushed; temperature 37.8 °C; pulse 92
AbdomenMild suprapubic tenderness; no loin tenderness
NeurologicalUnchanged from the last visit: light touch and vibration slightly reduced in the left fingertips, joint position normal, strength and reflexes as before, gait normal; no new sign
SkinNo rash

Problems

ProblemClinical statusVerificationCodeProvenance
Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this weekresolvedconfirmed R20.2S — Synthetic presenting problem anchored to her documented loss of sensation in her fingers and fatigue. Superseded by the diagnosis at the second visit.
Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 2017 McDonald criteria and the 2024 revision; synthetic modern detail linked to her documented diagnosisactiveconfirmed G35.AS — Synthetic course, imaging and laboratory detail; linked to her documented diagnosis in October 1973.
Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosisactiveconfirmed E55.9S — Synthetic finding.
Acute uncomplicated cystitis (Escherichia coli) seven weeks after the first ocrelizumab course, with a pseudo-relapse: two days of returning tingling in the fingers with a low fever and no new neurological deficit; resolvedactiveconfirmed N30.00S — Synthetic intercurrent infection; not a historical claim.

Assessment and Plan

Guideline basis: Multiple sclerosis in adults: management (NICE guideline NG220) (2022); Gupta K, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the IDSA and ESCMID. Clin Infect Dis 2011;52(5):e103-e120 (PMID 21292654) (2011)

Follow-up: Phone call in two days. Review with the re-baseline MRI in four weeks. Call for loin pain, high fever or any new neurological symptom. Next scheduled visit 2026-07-13: three months on ocrelizumab: re-baseline MRI, B-cell depletion, fatigue, vitamin D and hand function. [S]